I've flicked through announcements for the past 6 months, and all reference the expansion to other solid tumours such as breast and lung. So that part is definitely not a surprise.
Some announcements state phase II, some more specifically phase 1b/2a with dose escalation etc.
Maybe the FDA has advised a 1b only based on the proposed study design? Often part 1 of a study contibutes data for phase 1b and then an expansion arm of the study moves to phase 2b.
DARRT-2, page-4
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |